Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Singanayagam, Aran ^a   Glanville, Nicholas ^a   Girkin, Jason L ^b   Ching, Yee Man ^a   Marcellini, Andrea ^a   Porter, James D ^a   Toussaint, Marie ^a   Walton, Ross P ^a   Finney, Lydia J ^a   Aniscenko, Julia ^a   Zhu, Jie ^a   Trujillo Torralbo, Maria Belen ^a   Calderazzo, Maria Adelaide ^a   Grainge, Chris ^b   Loo, Su Ling ^b   Veerati, Punnam Chander ^b   Pathinayake, Prabuddha S ^b   Nichol, Kristy S ^b   Reid, Andrew T ^b   James, Phillip L ^a   Solari, Roberto ^a   Wark, Peter A B ^b   Knight, Darryl A ^b   Moffatt, Miriam F ^a   Cookson, William O ^a   Edwards, Michael R ^a   Mallia, Patrick ^a   Bartlett, Nathan W ^a,b   Johnston, Sebastian L ^a   more..

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA INTERFERON; BETA DEFENSIN 2; BETA INTERFERON; BUDESONIDE; CD69 ANTIGEN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; MANNOSE BINDING LECTIN 2; MUCIN 5AC; MUCIN 5B; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; PENTRAXIN 3; RECOMBINANT BETA INTERFERON; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR 3; ALPHA BETA INTERFERON RECEPTOR; CORTICOSTEROID; FLUTICASONE; IFNAR1 PROTEIN, MOUSE;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; HEALTH RISK; IMMUNE RESPONSE; IMMUNITY; INHIBITION; MUCUS; PEPTIDE; PNEUMONIA; PROTEIN; SECRETION;

ADAPTIVE IMMUNITY; ADULT; AGED; AIRWAY EPITHELIUM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BEAS-2B CELL LINE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DNA BINDING; DRUG MECHANISM; EXPIRATORY RESERVE VOLUME; FEMALE; FORCED VITAL CAPACITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INNATE IMMUNITY; MALE; MIDDLE AGED; MOUSE; MUCUS; MUCUS SECRETION; NATURAL KILLER CELL; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RHINOVIRUS; RHINOVIRUS INFECTION; VERY ELDERLY; VIRAL CLEARANCE; VIRUS LOAD; ANIMAL; BACTERIAL INFECTION; CELL LINE; DRUG EFFECT; GENETICS; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LUNG; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PICORNAVIRUS INFECTION; VIROLOGY;

BACTERIA (MICROORGANISMS); MUS; RHINOVIRUS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANIMALS; BACTERIAL INFECTIONS; BACTERIAL LOAD; CELL LINE; FLUTICASONE; HUMANS; IMMUNITY, INNATE; LUNG; MICE, KNOCKOUT; MUCUS; PICORNAVIRIDAE INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, INTERFERON ALPHA-BETA; RHINOVIRUS;

EID: 85048335549     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-04574-1     Document Type: Article

References (60)

1. Mallia, P. et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am. J. Respir. Crit. Care Med. 183, 734-742 (2011).
2. Message, S. D. et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc. Natl Acad. Sci. USA 105, 13562-13567 (2008).
3. Jackson, D. J. et al. IL-33-dependent type 2 inflammation during rhinovirusinduced asthma exacerbations in vivo. Am. J. Respir. Crit. Care Med. 190, 1373-1382 (2014).
4. Sykes, A. et al. Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar lavage cells in asthmatic patients. J. Allergy Clin. Immunol. 129, 1506-1514 e1506 (2012).
5. Wark, P. A. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med. 201, 937-947 (2005).
6. Contoli, M. et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat. Med. 12, 1023-1026 (2006).
7. Collison, A. et al. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. Nat. Med. 19, 232-237 (2013).
8. Hsu, A. C. et al. Impaired antiviral stress granule and IFN-beta enhanceosome formation enhances susceptibility to influenza infection in chronic obstructive pulmonary disease epithelium. Am. J. Respir. Cell Mol. Biol. 55, 117-127 (2016).
9. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Eng. J. Med. 356, 775-789 (2007).
10. Wedzicha, J. A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 177, 19-26 (2008).
11. Kardos, P., Wencker, M., Glaab, T. &Vogelmeier, C. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 144-149 (2007).
12. Calverley, P. M. et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 139, 505-512 (2011).
13. Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J. &Fan, E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300, 2407-2416 (2008).
14. Mallia, P. et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 186, 1117-1124 (2012).
15. Davies, J. M. et al. Budesonide and formoterol reduce early innate antiviral immune responses in vitro. PLoS ONE 6, e27898 (2011).
16. Thomas, B. J., Porritt, R. A., Hertzog, P. J., Bardin, P. G. &Tate, M. D. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci. Rep. 4, 7176 (2014).
17. Barnes, P. J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 131, 636-645 (2013).
18. Mitani, A., Ito, K., Vuppusetty, C., Barnes, P. J. &Mercado, N. Restoration of corticosteroid sensitivity in chronic obstructive pulmonary disease by inhibition of mammalian target of rapamycin. Am. J. Respir. Crit. Care Med. 193, 143-153 (2016).
19. Singam, R. et al. Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice. Virol. J. 3, 32 (2006).
20. Bartlett, N. W. et al. Defining critical roles for NF-kappaB p65 and type I interferon in innate immunity to rhinovirus. EMBO Mol. Med. 4, 1244-1260 (2012).
21. Wang, Q. et al. Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. J. Immunol. 183, 6989-6997 (2009).
22. Voynow, J. A. &Rubin, B. K. Mucins, mucus, and sputum. Chest 135, 505-512 (2009).
23. Slater, L. et al. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog. 6, e1001178 (2010).
24. Seth, R. B., Sun, L., Ea, C. K. &Chen, Z. J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NFkappaB and IRF 3. Cell 122, 669-682 (2005).
25. Singanayagam, A. et al. A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD. Clin. Sci. 129, 245-258 (2015).
26. Wu, W. et al. Human primary airway epithelial cells isolated from active smokers have epigenetically impaired antiviral responses. Respir. Res. 17, 111 (2016).
27. Skevaki, C. L. et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin. Exp. Allergy 39, 1700-1710 (2009).
28. Hsu, A. C. et al. MicroRNA-125a and-b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD. JCI Insight 2, e90443 (2017).
29. Footitt, J. et al. Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD. Chest 149, 62-73 (2016).
30. Gustafson, L. M., Proud, D., Hendley, J. O., Hayden, F. G. &Gwaltney, J. M. Jr. Oral prednisone therapy in experimental rhinovirus infections. J. Allergy Clin. Immunol. 97, 1009-1014 (1996).
31. Puhakka, T. et al. The common cold: effects of intranasal fluticasone propionate treatment. J. Allergy Clin. Immunol. 101, 726-731 (1998).
32. Farr, B. M. et al. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J. Infect. Dis. 162, 1173-1177 (1990).
33. Bartlett, N. W. et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med. 14, 199-204 (2008).
34. Matsukura, S. et al. Basic research on virus-induced asthma exacerbation: inhibition of inflammatory chemokine expression by fluticasone propionate. Int. Arch. Allergy Immunol. 161, 84-92 (2013). Suppl 2.
35. Kato, H. et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiationassociated gene 5. J. Exp. Med. 205, 1601-1610 (2008).
36. Hornung, V. et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314, 994-997 (2006).
37. Barclay, W. S., al-Nakib, W., Higgins, P. G. &Tyrrell, D. A. The time course of the humoral immune response to rhinovirus infection. Epidemiol. Infect. 103, 659-669 (1989).
38. Parry, D. E. et al. Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. J. Allergy Clin. Immunol. 105, 692-698 (2000).
39. Alper, C. M. et al. Prechallenge antibodies moderate disease expression in adults experimentally exposed to rhinovirus strain hanks. Clin. Infect. Dis. 27, 119-128 (1998).
40. McKinstry, K. K. et al. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J. Clin. Invest. 122, 2847-2856 (2012).
41. Yerkovich, S. T. et al. Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation. BMC Pulm. Med. 12, 37 (2012).
42. Aikawa, T. et al. Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 140, 477-482 (1989).
43. Vestbo, J., Prescott, E. &Lange, P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. 153, 1530-1535 (1996).
44. Groneberg, D. A. et al. Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology 40, 367-373 (2002).
45. Hewson, C. A. et al. Rhinovirus induces MUC5AC in a human infection model and in vitro via NF-kappaB and EGFR pathways. Eur. Respir. J. 36, 1425-1435 (2010).
46. Zhu, L. et al. Rhinovirus-induced major airway mucin production involves a novel TLR3-EGFR-dependent pathway. Am. J. Respir. Cell Mol. Biol. 40, 610-619 (2009).
47. Sato, K. et al. Cryptococcus neoformans infection in mice lacking type I interferon signaling leads to increased fungal clearance and IL-4-dependent mucin production in the lungs. PLoS ONE 10, e0138291 (2015).
48. Chalmers, J. D., Tebboth, A., Gayle, A., Ternouth, A. &Ramscar, N. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim. Care Respir. Med. 27, 43 (2017).
49. Abbinante-Nissen, J. M., Simpson, L. G. &Leikauf, G. D. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am. J. Physiol. 268, L601-L606 (1995).
50. Usmani, O. S. et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172, 704-712 (2005).
51. Kulkarni, N. N. et al. Glucocorticoid dexamethasone down-regulates basal and vitamin D3 induced cathelicidin expression in human monocytes and bronchial epithelial cell line. Immunobiology 221, 245-252 (2016).
52. Meyer, M. et al. Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers. Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L269-L276 (2014).
53. Gompertz, S., Bayley, D. L., Hill, S. L. &Stockley, R. A. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 56, 36-41 (2001).
54. Pant, S. et al. Airway inflammation and anti-protease defences rapidly improve during treatment of an acute exacerbation of COPD. Respirology 14, 495-503 (2009).
55. Parameswaran, G. I., Sethi, S. &Murphy, T. F. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest 140, 611-617 (2011).
56. Djukanovic, R. et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am. J. Respir. Crit. Care Med. 190, 145-154 (2014).
57. Suissa, S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 68, 540-543 (2013).
58. Ito, K. et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203, 7-13 (2006).
59. Bartlett, N. W., Singanayagam, A. &Johnston, S. L. Mouse models of rhinovirus infection and airways disease. Methods Mol. Biol. 1221, 181-188 (2015).
60. Donaldson, G. C., Seemungal, T. A., Bhowmik, A. &Wedzicha, J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57, 847-852 (2002).